GlassScriptPhysician profile
Robert A Oesterle
NPI 1053524116
$1,427.10
in general payments reported to CMS, 2019-2025
9 companies · $494 in 2025
The $494 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.00 · 2021: $35.80 · 2022: $486 · 2023: $56.20 · 2024: $340 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $889.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $696.19 | 2021-2025 | Ozempic, Rybelsus, Tresiba |
| Amgen INC. | $335.24 | 2022-2025 | Tepezza, Repatha |
| Amneal Pharmaceuticals LLC | $88.75 | 2025 | Unithroid |
| Sanofi-Aventis U.S. LLC | $88.03 | 2022-2023 | |
| Abbott Laboratories | $76.65 | 2019-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $47.44 | 2024 | Korlym |
| Lilly USA, LLC | $43.60 | 2023-2024 | |
| Tandem Diabetes Care, INC. | $26.94 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Horizon Therapeutics Plc | $24.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Oesterle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.